Association between programmed cell death ligand 1 expression and thyroid cancer
Authors:
Open Access
- 9 April 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (14) , e25315
Abstract
Background: Programmed cell death ligand 1 (PD-L1), which is highly expressed in a variety of malignant tumors, is closely related to clinicopathological features and prognosis. However, there are few studies on the potential effects of PD-L1 on thyroid carcinoma, the incidence of which has shown an upward trend worldwide. This study aimed to explore the association between PD-L1 expression and clinicopathological features and prognosis of thyroid cancer. Methods: An elaborate retrieval was performed using Medline, PubMed, Cochrane Library, EMBASE, Web of Science, WanFang databases, and China National Knowledge Infrastructure to determine the association between PD-L1 expression and disease-free survival (DFS), overall survival (OS), and clinicopathological features in patients with thyroid cancer. Study selection, data extraction, risk assessment, and data synthesis were performed independently by 2 reviewers. In this meta-analysis, RevMan 5.3 and Stata 15.1 were used for bias risk assessment and data synthesis. Results: After a detailed search, 2546 cases reported in 13 articles were included in this meta-analysis. The outcomes revealed that high expression of PD-L1 in patients with thyroid cancer was associated with poor DFS (hazard ratio [HR] = 3.37, 95% confidence interval [CI] 2.54–4.48, P < .00001) and OS (HR = 2.52, 95% CI: 1.20–5.32, P = .01). High PD-L1 expression was associated with tumor size ≥2 cm, tumor recurrence, extrathyroidal extension, concurrent thyroiditis, unifocal tumor, and absence of psammoma body (P < .05). Subgroup analysis showed that positive expression of PD-L1 was related to poor prognosis for DFS of non-medullary thyroid carcinoma, and the overexpression of PD-L1 in differentiated thyroid carcinoma (DTC) was related to tumor recurrence, concurrent thyroiditis, extrathyroidal extension, unifocal DTC, late stage DTC, and BRAFV600E mutation in DTC. Conclusion: PD-L1 is a significant predictor of prognosis and malignancy of thyroid cancer (especially DTC), and PD-L1 inhibitors may be a promising therapeutic option for refractory thyroid cancer in the future.Keywords
Funding Information
- the Natural Science Foundation of Hubei Province, China (2018CFB147)
- Study on the relationship between iodine and selenium nutrition status and thyroid function in pregnant women in Yichang (A18-301-14)
This publication has 44 references indexed in Scilit:
- Estimation of Out-of-Field Dose Variation using Markus Ionization Chamber DetectorSciMedicine Journal, 2020
- Dosimetry Study in Head and Neck of Anthropomorphic Phantoms in Computed Tomography ScansSciMedicine Journal, 2020
- Basis of PD1/PD-L1 TherapiesJournal of Clinical Medicine, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Heterogeneity of Thyroid CancerPathobiology, 2018
- Survival in Response to Multimodal Therapy in Anaplastic Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2017
- Thyroid cancerThe Lancet, 2016
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- An evidence‐based review of poorly differentiated thyroid cancerWorld Journal of Surgery, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006